Results 101 to 110 of about 47,015 (158)

Correspondence to editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease” [PDF]

Clinical and Molecular Hepatology
Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim   +3 more
doaj   +1 more source

Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice. [PDF]

J Intern Med
Newsome PN, Ajaz S.
europepmc   +1 more source

Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis” [PDF]

Clinical and Molecular Hepatology
Yuri Cho, Dae Won Jun
doaj   +1 more source

Metabolic dysfunction-associated steatohepatitis (MASH): intersections with type 2 diabetes and insulin resistance. [PDF]

Front Endocrinol (Lausanne)
Giannoukakis N.
europepmc   +1 more source

Clinical outcomes associated with GLP-1 receptor agonist use in metabolic dysfunction-associated steatohepatitis: A multinational cohort study. [PDF]

Medicine (Baltimore)
Khan SA, Subedi A, Marasini A, Shrestha A, Jha S, Kandel A, Basnet K, Karki S, Kamal M, Khan S, Kausar H, Parajuli SB, Dahiya DS.   +12 more
europepmc   +1 more source

Early Cardiotoxic Remodelling Precedes Hepatic Fibrosis and Increases Susceptibility to Lethal Arrhythmias in Wild-Type MASH Mice. [PDF]

Clin Exp Pharmacol Physiol
Liu J, Yamashita K, Yamano S.
europepmc   +1 more source

The menopause-obesity axis in MASH progression: from estrogen decline to liver fibrosis. [PDF]

Front Gastroenterol (Lausanne)
Ntikoudi A, Vlachou E.
europepmc   +1 more source

From Molecular Mechanisms to Clinical Strategies: A Comprehensive Overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). [PDF]

Int J Mol Sci
Świerczek D, Dreger M, Jatkowski J, Kancerek J, Drozdzowska B, Wojnicz R.   +5 more
europepmc   +1 more source

Glimpse into the role of Kupffer cells in a spheroid model of metabolic dysfunction-associated steatohepatitis (MASH)

Biology Open
Niklas Bogovic, Maria Drießlein, Marie Keller, Hans J. Schlitt, Edward K. Geissler, Lydia Schneider, Philipp Kreiner, Henrik Junger, Elke Eggenhofer   +8 more
doaj   +1 more source

Drug Development for MASH-Related Compensated Cirrhosis: Past, Present and Future. [PDF]

Liver Int
Zeng RQ, Shao YX, Lin RT, Shen XT, Sun QM, Xin X, Liu P, Fan JG, Hu YY, Feng Q.   +9 more
europepmc   +1 more source